FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT.

http://bit.ly/2FhELXr